Coherus BioSciences Analyst Ratings
Coherus BioSciences Analyst Ratings
While ratings are subjective and will change, the latest Coherus BioSciences (CHRS) rating was a reiterated with a price target of $0.00 to $12.00. The current price Coherus BioSciences (CHRS) is trading at is $2.00, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/28/2023 | 501.5% | Truist Securities | → $12 | Reiterates | Buy → Buy |
| 11/17/2023 | 451.38% | Baird | → $11 | Initiates Coverage On | → Outperform |
| 11/08/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 11/07/2023 | 551.63% | HC Wainwright & Co. | $20 → $13 | Maintains | Buy |
| 10/23/2023 | 250.88% | Barclays | $8 → $7 | Maintains | Overweight |
| 09/26/2023 | 902.51% | Truist Securities | → $20 | Reiterates | Buy → Buy |
| 09/26/2023 | 902.51% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/03/2023 | 902.51% | HC Wainwright & Co. | $24 → $20 | Maintains | Buy |
| 07/24/2023 | 501.5% | Citigroup | → $12 | Initiates Coverage On | → Buy |
| 07/14/2023 | 902.51% | Truist Securities | $22 → $20 | Maintains | Buy |
| 06/28/2023 | 1002.76% | Truist Securities | → $22 | Reiterates | Buy → Buy |
| 06/20/2023 | 1002.76% | Truist Securities | $24 → $22 | Maintains | Buy |
| 06/20/2023 | 1103.01% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 06/15/2023 | 1103.01% | Truist Securities | → $24 | Reiterates | Buy → Buy |
| 06/06/2023 | 1103.01% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 06/01/2023 | 1103.01% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 05/23/2023 | 301% | Barclays | $13 → $8 | Maintains | Overweight |
| 05/09/2023 | 1103.01% | HC Wainwright & Co. | $26 → $24 | Maintains | Buy |
| 05/01/2023 | 1103.01% | Truist Securities | → $24 | Initiates Coverage On | → Buy |
| 03/28/2023 | 451.38% | UBS | → $11 | Upgrades | Neutral → Buy |
| 03/08/2023 | 551.63% | Barclays | $15 → $13 | Maintains | Overweight |
| 03/07/2023 | 1203.26% | HC Wainwright & Co. | $30 → $26 | Maintains | Buy |
| 11/16/2022 | 952.63% | Mizuho | $28 → $21 | Maintains | Buy |
| 11/14/2022 | 451.38% | JP Morgan | $13 → $11 | Maintains | Neutral |
| 08/16/2022 | 1303.51% | Mizuho | $25 → $28 | Maintains | Buy |
| 06/14/2022 | 250.88% | UBS | → $7 | Initiates Coverage On | → Neutral |
| 05/20/2022 | 1153.13% | Mizuho | $30 → $25 | Maintains | Buy |
| 05/09/2022 | 651.88% | Barclays | $20 → $15 | Maintains | Overweight |
| 03/07/2022 | 651.88% | JP Morgan | → $15 | Downgrades | Overweight → Neutral |
| 11/09/2021 | 1403.76% | HC Wainwright & Co. | $36 → $30 | Maintains | Buy |
| 07/23/2021 | 1704.51% | HC Wainwright & Co. | $26 → $36 | Maintains | Buy |
| 05/17/2021 | 1103.01% | Barclays | $28 → $24 | Maintains | Overweight |
| 05/07/2021 | 1203.26% | HC Wainwright & Co. | $29 → $26 | Maintains | Buy |
| 02/25/2021 | 1353.63% | HC Wainwright & Co. | $33 → $29 | Maintains | Buy |
| 11/19/2020 | 1403.76% | Mizuho | $35 → $30 | Maintains | Buy |
| 11/06/2020 | 1504.01% | HC Wainwright & Co. | $33 → $32 | Maintains | Buy |
| 08/10/2020 | 1403.76% | Truist Securities | $26 → $30 | Maintains | Buy |
| 08/07/2020 | 1554.14% | HC Wainwright & Co. | $30 → $33 | Maintains | Buy |
| 07/16/2020 | 902.51% | B of A Securities | → $20 | Initiates Coverage On | → Neutral |
| 04/17/2020 | 1203.26% | SunTrust Robinson Humphrey | → $26 | Initiates Coverage On | → Buy |
| 02/28/2020 | 1403.76% | HC Wainwright & Co. | $29 → $30 | Reiterates | → Buy |
| 02/06/2020 | 1654.39% | JP Morgan | $33 → $35 | Maintains | Overweight |
| 11/07/2019 | 1453.88% | Citigroup | $27 → $31 | Maintains | Buy |
| 08/13/2019 | 2055.39% | Mizuho | → $43 | Initiates Coverage On | → Buy |
| 06/11/2019 | 1403.76% | Barclays | → $30 | Initiates Coverage On | → Overweight |
| 05/07/2019 | 1303.51% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/28/2023 | 501.5% | Truist 證券 | → 12 美元 | 重申 | 購買 → 購買 |
| 11/17/2023 | 451.38% | 貝爾德 | → 11 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 11/08/2023 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 11/07/2023 | 551.63% | HC Wainwright & Co. | 20 美元 → 13 美元 | 維護 | 購買 |
| 2023 年 10 月 23 日 | 250.88% | 巴克萊 | 8 美元 → 7 美元 | 維護 | 超重 |
| 09/26/2023 | 902.51% | Truist 證券 | → 20 美元 | 重申 | 購買 → 購買 |
| 09/26/2023 | 902.51% | HC Wainwright & Co. | → 20 美元 | 重申 | 購買 → 購買 |
| 08/03/2023 | 902.51% | HC Wainwright & Co. | 24 美元 → 20 美元 | 維護 | 購買 |
| 2023 年 7 月 24 日 | 501.5% | 花旗集團 | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/14/2023 | 902.51% | Truist 證券 | 22 美元 → 20 美元 | 維護 | 購買 |
| 06/28/2023 | 1002.76% | Truist 證券 | → 22 美元 | 重申 | 購買 → 購買 |
| 06/20/2023 | 1002.76% | Truist 證券 | 24 美元 → 22 美元 | 維護 | 購買 |
| 06/20/2023 | 1103.01% | HC Wainwright & Co. | → 24 美元 | 重申 | 購買 → 購買 |
| 06/15/2023 | 1103.01% | Truist 證券 | → 24 美元 | 重申 | 購買 → 購買 |
| 06/06/2023 | 1103.01% | HC Wainwright & Co. | → 24 美元 | 重申 | → 購買 |
| 06/01/2023 | 1103.01% | HC Wainwright & Co. | → 24 美元 | 重申 | 購買 → 購買 |
| 05/23/2023 | 301% | 巴克萊 | 13 美元 → 8 美元 | 維護 | 超重 |
| 05/09/2023 | 1103.01% | HC Wainwright & Co. | 26 美元 → 24 美元 | 維護 | 購買 |
| 05/01/2023 | 1103.01% | Truist 證券 | → 24 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/28/2023 | 451.38% | 瑞銀（UBS） | → 11 美元 | 升級 | 中性 → 買入 |
| 03/08/2023 | 551.63% | 巴克萊 | 15 美元 → 13 美元 | 維護 | 超重 |
| 03/07/2023 | 1203.26% | HC Wainwright & Co. | 30 美元 → 26 美元 | 維護 | 購買 |
| 11/16/2022 | 952.63% | 瑞穗市 | 28 美元 → 21 美元 | 維護 | 購買 |
| 11/14/2022 | 451.38% | 摩根大通 | 13 美元 → 11 美元 | 維護 | 中立 |
| 08/16/2022 | 1303.51% | 瑞穗市 | 25 美元 → 28 美元 | 維護 | 購買 |
| 06/14/2022 | 250.88% | 瑞銀（UBS） | → 7 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 05/20/2022 | 1153.13% | 瑞穗市 | 30 美元 → 25 美元 | 維護 | 購買 |
| 05/09/2022 | 651.88% | 巴克萊 | 20 美元 → 15 美元 | 維護 | 超重 |
| 03/07/2022 | 651.88% | 摩根大通 | → 15 美元 | 降級 | 超重 → 中性 |
| 2021 年 9 月 11 日 | 1403.76% | HC Wainwright & Co. | 36 美元 → 30 美元 | 維護 | 購買 |
| 2021 年 7 月 23 日 | 1704.51% | HC Wainwright & Co. | 26 美元 → 36 美元 | 維護 | 購買 |
| 05/17/2021 | 1103.01% | 巴克萊 | 28 美元 → 24 美元 | 維護 | 超重 |
| 05/07/2021 | 1203.26% | HC Wainwright & Co. | 29 美元 → 26 美元 | 維護 | 購買 |
| 2021 年 2 月 25 日 | 1353.63% | HC Wainwright & Co. | 33 美元 → 29 美元 | 維護 | 購買 |
| 2020 年 11 月 19 日 | 1403.76% | 瑞穗市 | 35 美元 → 30 美元 | 維護 | 購買 |
| 11/06/2020 | 1504.01% | HC Wainwright & Co. | 33 美元 → 32 美元 | 維護 | 購買 |
| 08/10/2020 | 1403.76% | Truist 證券 | 26 美元 → 30 美元 | 維護 | 購買 |
| 08/07/2020 | 1554.14% | HC Wainwright & Co. | 30 美元 → 33 美元 | 維護 | 購買 |
| 07/16/2020 | 902.51% | B of A 類證券 | → 20 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 2020 年 4 月 17 日 | 1203.26% | SunTrust 羅賓遜·漢弗萊 | → 26 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 2 月 28 日 | 1403.76% | HC Wainwright & Co. | 29 美元 → 30 美元 | 重申 | → 購買 |
| 02/06/2020 | 1654.39% | 摩根大通 | 33 美元 → 35 美元 | 維護 | 超重 |
| 11/07/2019 | 1453.88% | 花旗集團 | 27 美元 → 31 美元 | 維護 | 購買 |
| 08/13/2019 | 2055.39% | 瑞穗市 | → 43 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2019 年 11 月 6 日 | 1403.76% | 巴克萊 | → 30 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 05/07/2019 | 1303.51% | HC Wainwright & Co. | → 28 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Coherus BioSciences (CHRS)?
Coherus BioSciences（CHRS）的目標價格是多少？
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Truist Securities on November 28, 2023. The analyst firm set a price target for $12.00 expecting CHRS to rise to within 12 months (a possible 501.50% upside). 22 analyst firms have reported ratings in the last year.
Truist Securities於2023年11月28日公佈了Coherus BioSciences（納斯達克股票代碼：CHRS）的最新目標股價。該分析公司將目標股價定爲12.00美元，預計CHRS將在12個月內上漲至12個月（可能上漲501.50％）。去年有22家分析公司公佈了評級。
What is the most recent analyst rating for Coherus BioSciences (CHRS)?
Coherus BioSciences（CHRS）的最新分析師評級是多少？
The latest analyst rating for Coherus BioSciences (NASDAQ: CHRS) was provided by Truist Securities, and Coherus BioSciences reiterated their buy rating.
Coherus BioSciences（納斯達克股票代碼：CHRS）的最新分析師評級由Truist Securities提供，Coherus BioSciences重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Coherus BioSciences (CHRS)?
Coherus BioSciences（CHRS）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coherus BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coherus BioSciences was filed on November 28, 2023 so you should expect the next rating to be made available sometime around November 28, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Coherus BioSciences的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Coherus BioSciences的最後一次評級是在2023年11月28日提交的，因此您應該預計下一個評級將在2024年11月28日左右公佈。
Is the Analyst Rating Coherus BioSciences (CHRS) correct?
分析師評級Coherus BioSciences（CHRS）是否正確？
While ratings are subjective and will change, the latest Coherus BioSciences (CHRS) rating was a reiterated with a price target of $0.00 to $12.00. The current price Coherus BioSciences (CHRS) is trading at is $2.00, which is within the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的Coherus BioSciences（CHRS）評級得到了重申，目標股價爲0.00美元至12.00美元。Coherus BioSciences（CHRS）目前的交易價格爲2.00美元，在分析師的預測區間內。
